Clinical Trial Search

Primary: Number of Participants Monitored for Long-term Safety of Valbenazine — 35; 117; 8 Participants

Primary: Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases — 124; 208 HOURS

Primary: Uterine Contractions — 3.18; 3.78; 3.20 minutes

Primary: Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA). — 75.0; 87.5 percentage of participants analyzed — p=0.002

Primary: Prevalence of Different Neurological Disorders Associated With Depression Treated With Fluvoxamine (Fevarin®). — 49.2; 31.8; 20.1; 2.7 Percentage

Primary: Maximum Observed Plasma Concentration (Cmax) of Talazoparib — 8.4 nanogram per milliliter (ng/mL)

Primary: Progression Free Survival (PFS) — 18.14; NA Months

Primary: Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug — 78.6; 66.7; 78.9; 91.7 percentage of participants

Primary: Craving Response to Trier Social Stress Task — 16.18; 16.69 units on a scale

Primary: Number of Subjects Reporting Solicited Local Symptoms — 1; 0; 2; 0 Participants

Primary: Incidence of Intra-Operative Hemostatic Interventions — 1.8 Percentage of vessel transections

Primary: Smoking Abstinence — 4; 8 Participants — p=.52

Primary: Seropositivity Rate Measured by Neutralization Test (NT) at 21-35 Days After the First Tick-borne Encephalitis (TBE) Booster Vaccination in Study 700401 — 100.0…

Primary: Number of Participants With Combination of Gastrointestinal Tract Colonization With Multi-drug Resistant Gram-negative Bacteria, C. Difficile and VRE — 8; 8 Participants

Primary: Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations — 295 Participants